Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at evading eradication ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Despite Uganda's steady progress in reducing HIV infections and AIDS-related deaths, men remain disproportionately affected due to low uptake of antiretroviral treatment (ARVs), the Uganda AIDS ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

A fish and chip shop owner has credited a charity which has supported him for more than 20 years after receiving his HIV diagnosis with ...

Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there had been around 1,200 new cases per year. But after many years of decline, ...

Uganda has recorded major gains against HIV, with significant declines in prevalence, new infections, and AIDS-related deaths, but emerging concerns among young people and persistent mother-to-child ...